| pubmed-article:10946808 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:10946808 | lifeskim:mentions | umls-concept:C0206074 | lld:lifeskim |
| pubmed-article:10946808 | lifeskim:mentions | umls-concept:C0242966 | lld:lifeskim |
| pubmed-article:10946808 | lifeskim:mentions | umls-concept:C0019116 | lld:lifeskim |
| pubmed-article:10946808 | lifeskim:mentions | umls-concept:C0392747 | lld:lifeskim |
| pubmed-article:10946808 | lifeskim:mentions | umls-concept:C0549178 | lld:lifeskim |
| pubmed-article:10946808 | lifeskim:mentions | umls-concept:C0443172 | lld:lifeskim |
| pubmed-article:10946808 | pubmed:issue | 4 | lld:pubmed |
| pubmed-article:10946808 | pubmed:dateCreated | 2001-2-2 | lld:pubmed |
| pubmed-article:10946808 | pubmed:abstractText | Endothelial damage and hemostatic imbalance play an important role in the evolution of the Systemic Inflammatory Response Syndrome (SIRS) into the Multiple Organ Dysfunction Syndrome (MODS). In Acute Renal Failure associated with SIRS, different types of Continuous Renal Replacement Therapies (CRRT) may give non-renal benefits by modifying the levels of some factors related to those disturbances. | lld:pubmed |
| pubmed-article:10946808 | pubmed:language | eng | lld:pubmed |
| pubmed-article:10946808 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10946808 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:10946808 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:10946808 | pubmed:issn | 1121-8428 | lld:pubmed |
| pubmed-article:10946808 | pubmed:author | pubmed-author:RochaEE | lld:pubmed |
| pubmed-article:10946808 | pubmed:author | pubmed-author:PurroyAA | lld:pubmed |
| pubmed-article:10946808 | pubmed:author | pubmed-author:LavillaF JFJ | lld:pubmed |
| pubmed-article:10946808 | pubmed:author | pubmed-author:García-Fernán... | lld:pubmed |
| pubmed-article:10946808 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:10946808 | pubmed:volume | 13 | lld:pubmed |
| pubmed-article:10946808 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:10946808 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:10946808 | pubmed:pagination | 282-9 | lld:pubmed |
| pubmed-article:10946808 | pubmed:dateRevised | 2010-11-18 | lld:pubmed |
| pubmed-article:10946808 | pubmed:meshHeading | pubmed-meshheading:10946808... | lld:pubmed |
| pubmed-article:10946808 | pubmed:meshHeading | pubmed-meshheading:10946808... | lld:pubmed |
| pubmed-article:10946808 | pubmed:meshHeading | pubmed-meshheading:10946808... | lld:pubmed |
| pubmed-article:10946808 | pubmed:meshHeading | pubmed-meshheading:10946808... | lld:pubmed |
| pubmed-article:10946808 | pubmed:meshHeading | pubmed-meshheading:10946808... | lld:pubmed |
| pubmed-article:10946808 | pubmed:meshHeading | pubmed-meshheading:10946808... | lld:pubmed |
| pubmed-article:10946808 | pubmed:meshHeading | pubmed-meshheading:10946808... | lld:pubmed |
| pubmed-article:10946808 | pubmed:meshHeading | pubmed-meshheading:10946808... | lld:pubmed |
| pubmed-article:10946808 | pubmed:articleTitle | Haemostatic changes in systemic inflammatory response syndrome during continuous renal replacement therapy. | lld:pubmed |
| pubmed-article:10946808 | pubmed:affiliation | Dept. of Nephrology, University Clinic of Navarra, School of Medicine, University of Navarra, Pamplona, Spain. | lld:pubmed |
| pubmed-article:10946808 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:10946808 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:10946808 | pubmed:publicationType | Randomized Controlled Trial | lld:pubmed |
| pubmed-article:10946808 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
